2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 271-273
Improving outcomes for relapsed/refractory CLL/SLL
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult
PAPER

253 Safety and efficacy of surovatamig, a novel, fully human, IgG4, CD19xCD3 bispecific T-cell engager (TCE), in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Matthew S Davids, MD, MMSc, Prof. Dr. Max Topp, MD2, Ki-Seong Eom, MD, PhD3, Hans Herluf Bentzen, MD4, Vincent Ribrag, MD5, David Lewis, PhD, MBChB6, Ryan Jacobs7, Shenmiao Yang8, Tae Min Kim, MD, PhD9, Yinhsun Feng, PhD10, Clémentine Sarkozy, MD,PhD11, Guillaume Cartron, MD12, Javier López Jimenez, MD, PhD13, Joshua D. Brody, MD14, Jithendra Kini Bailur15, Ping Hu16, Donghyun Ahn17, Matthew Stankowicz, PharmD18, Nikolaus Jahn19, Martin Hutchings, MD20
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 University Hospital of Würzburg, Würzburg, Germany
3 Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Rep. of South
4 Aarhus University Hospital, Aarhus, Denmark
5 Institut Gustave Roussy, Villejuif, France
6 University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
7 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
8 Peking University People’s Hospital, Beijing, China
9 Seoul National University Hospital, Seoul, Korea, Rep. of South
10 Chi Mei Medical Center, Tainan City, Taiwan
11 Institut Curie - Hôpital Rene Huguenin, Saint-Cloud, France
12 CHU Montpellier - Saint Éloi, Montpellier, France
13 Hospital Universitario Ramón y Cajal, IRYCIS, Universidad Alcalá de Henares, Madrid, Spain
14 Mount Sinai Hospital, New York, New York, United States
15 AstraZeneca, Waltham, Massachusetts, United States
16 AstraZeneca, Waltham, Massachusetts, United States
17 AstraZeneca, Gaithersburg, Maryland, United States
18 AstraZeneca, Gaithersburg, Maryland, United States
19 AstraZeneca, San Francisco, California, United States
20 Rigshospitalet and University of Copenhagen, Copenhagen, Denmark

Background: Pts with R/R CLL/SLL have limited treatment options and poor outcomes following prior Bruton’s tyrosine kinase and B-cell lymphoma 2 inhibitor (BTKi/BCL2i) therapy. Given the known patterns of resistance associated with BTKi and BCL2i, novel modes of action are needed to address unmet needs for pts with CLL/SLL. CD19 is a well-validated therapeutic target in CLL, with expression maintained after BTKi/BCL2i exposure. Surovatamig is a novel, fully human, IgG4, CD19xCD3 bispecific TCE with a unique, low-affinity anti-CD3 domain to reduce the risk of TCE-mediated toxicities. Surovatamig has shown encouraging clinical activity with manageable immune-mediated toxicity in pts with R/R non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. SOUNDTRACK-E (NCT06564038) is an ongoing, Phase 1/2, open-label, global, multicenter study of surovatamig in mature B-cell malignancies. We report preliminary safety, efficacy, and pharmacodynamic data from Cohort 1A, the first clinical evaluation of surovatamig in CLL/SLL and the first to test subcutaneous (SC) delivery of surovatamig.

Methods: Cohort 1A is enrolling pts with CLL/SLL aged ≥18 years and ≥2 prior lines of therapy (pLOT), including prior BTKi and/or BCL2i. Surovatamig is administered SC in 28-day cycles for up to 12 cycles, using double step-up dosing (2SUD [n=17]: Cycle [C]1 Day [D]1 and C1D8, with target dose [TD] on D15) or triple SUD (3SUD [n=5]: C1D1, D8 and D15, with TD on D22 and C2D1), and then TD every 2 weeks (switching to every 4 weeks after C6 for pts achieving a complete response [CR]). Primary endpoints include incidence and severity of adverse events (AEs) and dose-limiting toxicities (DLTs); secondary endpoints include clinical activity and pharmacokinetics (PK). Responses are assessed by investigator per 2018 International Workshop on CLL criteria for CLL or Lugano criteria for SLL. Biomarker analyses include serum cytokines.

Results: As of July 21, 2026, 22 pts received SC surovatamig at dose level (DL)1 (2.4 mg; n=5), DL2 (7.2 mg; n=3), DL3 (15 mg; n=10) and DL4 (25 mg; n=4). Median (range) duration of exposure was 1.6 (0–12) months. Median (range) age was 71 (30–83) years. Of 22 pts, 19 (86%) pts were double-exposed to prior BTKi/BCL2i. Baseline CD19 expression was confirmed in 19 (86%) pts and was negative in one pt, with data missing for two pts. At data cutoff, 12 pts are receiving ongoing treatment with surovatamig.

The most common treatment-emergent AEs (TEAEs) were cytokine release syndrome (CRS; 68%), neutropenia (36%), anemia (32%) and thrombocytopenia (27%). Neutropenia was transient and did not translate to any febrile neutropenia events. All CRS events were low grade (Gr; Gr 1: 41%, Gr 2: 23%) and limited to C1. No immune effector cell-associated neurotoxicity syndrome (ICANS) events were reported. One DLT (a transient asymptomatic Gr 3 atrial fibrillation after the first SUD) resolved without preventing dosing to the TD. Two Gr ≥3 infections were reported, including one unrelated fatal Pneumocystis jirovecii pneumonia (PJP) in a pt with low baseline CD4 count and recent fludarabine exposure without PJP prophylaxis. No treatment-related discontinuations occurred.

Among 12 response-evaluable pts, the overall response rate was 58% (7/12 pts), including two CRs (17%).

Proinflammatory cytokine levels, including IFN-γ and IL-6, rose transiently after each SUD and were highest after the first TD. Higher cytokine levels tended to be associated with CRS. Absolute levels remained lower than those reported in prior intravenous surovatamig studies, suggesting a mitigating effect of SC administration on cytokine release.

Conclusions: In this first report of surovatamig in heavily pretreated R/R CLL/SLL, SC monotherapy showed promising clinical activity with a manageable safety profile. CRS was entirely limited to low-grade events, and no ICANS was observed. As dose escalation is ongoing, preliminary efficacy data (including measurable residual disease), safety, PK, and additional pt data will be presented. These findings support the continued development of this novel CD19xCD3 TCE for the treatment of pts with CLL/SLL.

Matthew S Davids, MD, MMSc: AstraZeneca - Honoraria; AbbVie - Honoraria; Janssen - Honoraria; Ascentage Pharma - Honoraria; BMS - Honoraria; Nuvalent - Honoraria; BeOne Medicines - Honoraria; Schroedinger - Honoraria; Merck - Honoraria; Genentech - Honoraria; Genmab - Honoraria; Eli Lilly - Honoraria; Ascentage Pharma - Research Funding; AstraZeneca - Research Funding; Janssen - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Ascentage Pharma - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Schroedinger - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Nuvalent - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)